Clinical trials on CAR T-cell therapy for childhood cancer need geographic representation in lower income countries

Childhood cancer poses a critical challenge in global health, characterized by significant disparities in access to diagnosis and treatment, particularly in low- and middle-income countries (LMIC)[1]. Advanced therapies, such as chimeric antigen receptor (CAR) T-cell therapy, have transformed the treatment of certain pediatric cancers, providing new hope for patients with refractory or relapsed diseases[1]. However, the availability and accessibility of these treatments largely depend on the geographic and income distribution of clinical research.